1.Medical Expenditure of National Health Insurance Attributable to Smoking among the Korean Population.
Sang Yi LEE ; Sun Ha JEE ; Ji Eun YUN ; Su Young KIM ; Jakyung LEE ; Jonathan M SAMET ; Il Soon KIM
Journal of Preventive Medicine and Public Health 2007;40(3):227-232
OBJECTIVES: The purpose of this study was to determine the population-attributable risk (PAR) and estimate the total medical expenditure of the Korean National Health Insurance (KNHI) due to smoking. METHODS: We used data from the Korean Cancer Prevention Study of 1,178,138 Koreans aged 30 to 95. These data were available from 1992 to 2003 and covered a long-term follow-up period among the Korean population. RESULTS: The total medical expenditure of KNHI related to smoking increased by 27% from $324.9 million in 1999 to $413.7 million in 2003. By specific diseases, smokingattributable KNHI medical expenditure was the highest for lung cancer ($74.2 million), followed by stroke ($65.3 million), COPD ($50.1 million), CHD ($49 million) and stomach cancer ($30 million). A total of 1.3 million KNHI patients were suffering from smoking-related diseases in 2003. We predicted rises in total KNHI medical expenditure related to smoking to $675.1 million (63% increase compared with that of 2003) and in the total number of KNHI patients suffering from smoking-related diseases to about 2.6million (an approximate 100% increase compared with those in 2003) in 2015. CONCLUSIONS: We found a substantial economic burden related to the high smoking prevalence in South Korea.
Adult
;
Aged
;
Aged, 80 and over
;
Female
;
*Health Expenditures
;
Humans
;
Korea/epidemiology
;
Male
;
Middle Aged
;
Models, Econometric
;
National Health Programs/*economics
;
Risk
;
Smoking/adverse effects/*economics
2.Summary of report on cardiovascular diseases in China, 2012.
Wen WANG ; Sheng Shou HU ; Ling Zhi KONG ; Run Lin GAO ; Man Lu ZHU ; Wang Yong Jun WANG ; Zhao Su WU ; Wei Wei CHEN ; Jin Gang YANG ; Li Yuan MA ; Ming Bo LIU ; null
Biomedical and Environmental Sciences 2014;27(7):552-558
Cardiovascular Agents
;
economics
;
therapeutic use
;
Cardiovascular Diseases
;
congenital
;
epidemiology
;
etiology
;
China
;
epidemiology
;
Dyslipidemias
;
complications
;
Humans
;
Motor Activity
;
Nutritional Status
;
Overweight
;
Prevalence
;
Renal Insufficiency, Chronic
;
complications
;
Risk Factors
;
Smoking
;
adverse effects
;
Time Factors